1-[(2S,3R)-2-(hydroxymethyl)-3-[4-[(E)-oct-1-enyl]phenyl]pyrrolidin-1-yl]ethanone
C21H31NO2 — CID 155525567
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[(2S,3R)-2-(hydroxymethyl)-3-[4-[(E)-oct-1-enyl]phenyl]pyrrolidin-1-yl]ethanone
1-[(2S,3R)-2-(hydroxymethyl)-3-[4-[(E)-oct-1-enyl]phenyl]pyrrolidin-1-yl]ethanone (PubChem CID 155525567) has the molecular formula C21H31NO2 and a molecular weight of 329.48 g/mol. Its IUPAC name is 1-[(2S,3R)-2-(hydroxymethyl)-3-[4-[(E)-oct-1-enyl]phenyl]pyrrolidin-1-yl]ethanone.
Molecular Properties
| Compound Name | 1-[(2S,3R)-2-(hydroxymethyl)-3-[4-[(E)-oct-1-enyl]phenyl]pyrrolidin-1-yl]ethanone |
|---|---|
| PubChem CID | 155525567 |
| Molecular Formula | C21H31NO2 |
| Molecular Weight | 329.48 g/mol |
| Exact Mass | 329.24 |
| IUPAC Name | 1-[(2S,3R)-2-(hydroxymethyl)-3-[4-[(E)-oct-1-enyl]phenyl]pyrrolidin-1-yl]ethanone |
| SMILES | CCCCCC/C=C/c1ccc([C@H]2CCN(C(C)=O)[C@@H]2CO)cc1 |
| InChI | InChI=1S/C21H31NO2/c1-3-4-5-6-7-8-9-18-10-12-19(13-11-18)20-14-15-22(17(2)24)21(20)16-23/h8-13,20-21,23H,3-7,14-16H2,1-2H3/b9-8+/t20-,21-/m1/s1 |
| InChIKey | SDKNLXUTEMIAES-OBDVNYBASA-N |
| XLogP | 4.37 |
| TPSA | 40.54 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 2 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 24 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 329.48 |
| LogP ≤ 5 | 4.37 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 2 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155525567 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.